Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Science ; 377(6606): 572-574, 2022 08 05.
Artigo em Inglês | MEDLINE | ID: mdl-35926052

RESUMO

Data sharing among regulators must be "business as usual".


Assuntos
Saúde Global , Disseminação de Informação , United States Food and Drug Administration , Estados Unidos
7.
JAMA ; 317(14): 1461-1470, 2017 04 11.
Artigo em Inglês | MEDLINE | ID: mdl-28324029

RESUMO

Importance: Recent discussion has focused on questions related to the repeal and replacement of portions of the Affordable Care Act (ACA). However, issues central to the future of health and health care in the United States transcend the ACA provisions receiving the greatest attention. Initiatives directed to certain strategic and infrastructure priorities are vital to achieve better health at lower cost. Objectives: To review the most salient health challenges and opportunities facing the United States, to identify practical and achievable priorities essential to health progress, and to present policy initiatives critical to the nation's health and fiscal integrity. Evidence Review: Qualitative synthesis of 19 National Academy of Medicine-commissioned white papers, with supplemental review and analysis of publicly available data and published research findings. Findings: The US health system faces major challenges. Health care costs remain high at $3.2 trillion spent annually, of which an estimated 30% is related to waste, inefficiencies, and excessive prices; health disparities are persistent and worsening; and the health and financial burdens of chronic illness and disability are straining families and communities. Concurrently, promising opportunities and knowledge to achieve change exist. Across the 19 discussion papers examined, 8 crosscutting policy directions were identified as vital to the nation's health and fiscal future, including 4 action priorities and 4 essential infrastructure needs. The action priorities-pay for value, empower people, activate communities, and connect care-recurred across the articles as direct and strategic opportunities to advance a more efficient, equitable, and patient- and community-focused health system. The essential infrastructure needs-measure what matters most, modernize skills, accelerate real-world evidence, and advance science-were the most commonly cited foundational elements to ensure progress. Conclusions and Relevance: The action priorities and essential infrastructure needs represent major opportunities to improve health outcomes and increase efficiency and value in the health system. As the new US administration and Congress chart the future of health and health care for the United States, and as health leaders across the country contemplate future directions for their programs and initiatives, their leadership and strategic investment in these priorities will be essential for achieving significant progress.


Assuntos
Participação da Comunidade , Atenção à Saúde/organização & administração , Custos de Cuidados de Saúde , Prioridades em Saúde , National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division , Poder Psicológico , Pesquisa Biomédica , Medicina Baseada em Evidências , Instalações de Saúde , Pessoal de Saúde/educação , Disparidades em Assistência à Saúde , Humanos , Reembolso de Incentivo , Estados Unidos
12.
Sci Transl Med ; 4(163): 163fs43, 2012 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-23209277

RESUMO

The FDA announces a partnership with a new nonprofit organization--the Medical Device Innovation Consortium--to advance regulatory science in the medical technology arena.


Assuntos
Equipamentos e Provisões , Estados Unidos , United States Food and Drug Administration
14.
Regul Toxicol Pharmacol ; 62(3): 471-3, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22342950

RESUMO

As a first step in the implementation of the Food and Drug Administration's (FDA) Pathway to Global Product Safety and Quality (Anonymous, 2011), FDA's Office of International Programs (OIP) and the National Center for Toxicological Research (NCTR) sponsored a Global Summit on Regulatory Science Research and Innovation. Through a series of presentations and panel discussions, the Global Summit participants explored how research could be used more effectively as a tool for advancing regulatory science, food safety, medical technologies, and public health. Speakers provided an overview of each of the components in the global regulatory-science research initiative, including scientific innovation and modernizing toxicology; and discussed how the integration of these components is needed to achieve the promise of regulatory science at the global level. All participants agreed with the formation of a Global Coalition of Regulatory Research Scientists who will work collaboratively to build knowledge, promote the development of regulatory science, discover novel ways to clearly define research needs, and improve public health.


Assuntos
Pesquisa Biomédica/legislação & jurisprudência , Saúde Global/legislação & jurisprudência , Inovação Organizacional , Animais , Arkansas , Pesquisa Biomédica/tendências , Saúde Global/tendências , Humanos , Saúde Pública/legislação & jurisprudência , Saúde Pública/tendências
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...